ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Shionogi & Co., Ltd.

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022 JPYUSD
Revenue335,138M2,982.37M
Gross Profit272,411M2,424.17M
Operating income111,480M992.05M
Income before tax126,288M1,123.83M
Net income114,185M1,016.12M
EBITDA127,773M1,137.04M
Diluted EPS378.623.36
Dividends Per Share1151.02
Total Assets1,150.60B9,479.72M
Total liabilities157,052M1,293.94M
Total equity975,661M8,038.40M
Operating cash flow102,068M908.29M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 344,667M 367,960M 333,371M 297,177M 335,138M
Gross Profit 270,756M 305,713M 270,117M 238,000M 272,411M
Operating income 115,219M 168,370M 130,609M 95,694M 111,480M
Income before tax 137,378M 174,043M 158,516M 143,018M 126,288M
Net income 108,866M 137,190M 122,193M 111,858M 114,185M
EBITDA 134,226M 187,074M 144,649M 110,403M 127,773M
Diluted EPS 337.42 434.70 395.28 364.88 378.62
Dividends Per Share 82 94 103 108 115
Total Assets 711,463M 938,540M 873,695M 998,992M 1,150.60B
Total liabilities 106,619M 125,125M 108,186M 134,156M 157,052M
Total equity 601,374M 808,774M 765,152M 846,108M 975,661M
Operating cash flow 129,790M 165,000M 131,940M 109,039M 102,068M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 3,109.80M 3,318.10M 3,066.16M 2,802.03M 2,982.37M
Gross Profit 2,442.93M 2,756.78M 2,484.38M 2,244.06M 2,424.17M
Operating income 1,039.57M 1,518.28M 1,201.26M 902.28M 992.05M
Income before tax 1,239.51M 1,569.44M 1,457.94M 1,348.49M 1,123.83M
Net income 982.25M 1,237.11M 1,123.86M 1,054.69M 1,016.12M
EBITDA 1,211.07M 1,686.95M 1,330.40M 1,040.97M 1,137.04M
Diluted EPS 3.04 3.92 3.63 3.44 3.36
Dividends Per Share 0.73 0.84 0.94 1.01 1.02
Total Assets 6,689.82M 8,479.37M 8,093.14M 9,040.65M 9,479.72M
Total liabilities 1,002.52M 1,130.46M 1,002.13M 1,214.08M 1,293.94M
Total equity 5,654.66M 7,306.98M 7,087.69M 7,657.08M 8,038.40M
Operating cash flow 1,171.04M 1,487.89M 1,213.51M 1,028.11M 908.29M

Valuation Measures

Mar 2022
PER19.88
ROA10.62%
ROE12.53%
Operating margin33.26%
Profit margin34.07%

Key executives

  • Chairman & President: Isao Teshirogi
  • Manager-Accounting & Finance: Yuji Hosogai
  • Senior Executive Officer & GM-Research: Yasuetsu Imune
  • Senior Executive Officer, Head-R&D: John Keller
  • Executive Officer & GM-Reliability Guarantee: Takeshi Shiota

Shareholders

  • Nomura Asset Management Co., Ltd. (6.8%)
  • Sumitomo Life Insurance Co. (5.9%)
  • Shionogi & Co., Ltd. (3.8%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.2%)
  • Sumitomo Mitsui Banking Pension Fund (3.0%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • Daiwa Asset Management Co. Ltd. (2.7%)
  • Nippon Life Insurance Co. (2.6%)
  • Capital Research & Management Co. (World Investors) (2.6%)
  • The Vanguard Group, Inc. (2.4%)

Contact Details

Related Companies

  • Shionogi infectious Disease research Foundation
  • Shionogi Singapore Pte Ltd.
  • Shionogi Marketing Solutions Co., Ltd.
  • Shionogi Pharmacovigilance Center Co., Ltd.
  • Shionogi Business Partner Co., Ltd.
  • Shionogi Digital Science Co., Ltd
  • Shionogi Career Development Center Co., Ltd.
  • Shionogi TechnoAdvance Research Co., Ltd.
  • Shionogi BV
  • Shionogi Pharma Co., Ltd.
  • Shionogi Healthcare Co. Ltd.
  • Shionogi & Co., Ltd. /2 Subsidiaries/
  • Shionogi & Co. Restricted Stock Compensation Plan
  • Shionogi Healthcare & Co., Ltd.
  • Pionnier KK
  • Shionogi USA Holdings, Inc.
  • Beijing Shionogi Pharmaceutical Technology Ltd.
  • Shionogi Ltd.
  • Ezose Sciences, Inc.
  • Shionogi, Inc.
  • Shionogi Institute for Medical Science
  • Aburahi Laboratories
  • Taiwan Shionogi & Co., Ltd.
  • Shionogi Pharma Chemicals Co., Ltd.
  • Shionogi General Service Co., Ltd.
  • Shionogi Bunseki Center KK
  • Shionogi Ireland Ltd.
  • Shionogi Engineering Service Co. Ltd.
  • UMN Pharma, Inc.
  • Shionogi Bioresearch Corp.

Competitors

  • Nabriva Therapeutics Plc
  • NeuroBo Pharmaceuticals, Inc.
  • Vaxart, Inc.
  • Cocrystal Pharma Inc
  • Trevi Therapeutics, Inc.
  • Spero Therapeutics, Inc.
  • TaiMed Biologics Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Iterum Therapeutics plc
  • Atea Pharmaceuticals, Inc.
  • Vir Biotechnology, Inc.
  • Acura Pharmaceuticals, Inc.
  • aTyr Pharma, Inc.
  • Arbutus Biopharma Corporation
  • BELLUS Health Inc.
  • Surface Oncology, Inc.
  • Terns Pharmaceuticals, Inc.
  • Zynerba Pharmaceuticals Inc
Last Updated on 28 Nov, 2022

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more